Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.55 |
| ▸ | ACACA | Q13085 | 8/20 | 0.55 |
| ▸ | ACACB | O00763 | 6/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315488 | 0.91 | ACACB (0.46) | ITGB3ITGA2BACACAACACBPKM | |
| SCHEMBL25315090 | 0.90 | ACACB (0.47) | ITGB3ITGA2BACACAACACBPKM | |
| SCHEMBL10111315 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BACACAACACBGPR119 | |
| SCHEMBL25313895 | 0.83 | CYP3A4 (0.58) | PKMGPR119 | |
| SCHEMBL21753329 | 0.83 | ACACA (0.53) | ITGB3ITGA2BACACAACACBJAK2 | |
| SCHEMBL2695429 | 0.82 | HDAC1 (0.53) | ITGB3ITGA2BPKMJAK2JAK1 | |
| SCHEMBL18319201 | 0.82 | OPRM1 (0.56) | ITGB3ITGA2BACACAACACBPKM | |
| SCHEMBL10127145 | 0.81 | ACACB (0.53) | ITGB3ITGA2BACACAACACB | |
| SCHEMBL675555 | 0.80 | PKM (0.47) | PKMJAK2JAK1 | |
| SCHEMBL2301444 | 0.80 | ITGB3 (0.50) | ITGB3ITGA2BACACAACACBHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427465-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| WO-2010129729-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | SSTR5, SSTR2, GPR119 | ITGB3 2791/4885ITGA2B 1602/4885ACACA 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.